EA202092036A1 - Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a - Google Patents

Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a

Info

Publication number
EA202092036A1
EA202092036A1 EA202092036A EA202092036A EA202092036A1 EA 202092036 A1 EA202092036 A1 EA 202092036A1 EA 202092036 A EA202092036 A EA 202092036A EA 202092036 A EA202092036 A EA 202092036A EA 202092036 A1 EA202092036 A1 EA 202092036A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonist
receptor
pyrazolotriazolopyrimidine
derivatives
stereoisomer
Prior art date
Application number
EA202092036A
Other languages
English (en)
Russian (ru)
Inventor
Голян Чжан
Чаню Чжоу
Original Assignee
Бейджин, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бейджин, Лтд. filed Critical Бейджин, Лтд.
Publication of EA202092036A1 publication Critical patent/EA202092036A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA202092036A 2018-04-08 2019-04-08 Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a EA202092036A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018082140 2018-04-08
PCT/CN2019/081785 WO2019196803A1 (en) 2018-04-08 2019-04-08 Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist

Publications (1)

Publication Number Publication Date
EA202092036A1 true EA202092036A1 (ru) 2021-01-28

Family

ID=68163465

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092036A EA202092036A1 (ru) 2018-04-08 2019-04-08 Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a

Country Status (15)

Country Link
US (1) US11472811B2 (https=)
EP (1) EP3774813A4 (https=)
JP (1) JP2021520392A (https=)
KR (1) KR20200140849A (https=)
CN (1) CN112313234B (https=)
AU (1) AU2019251148A1 (https=)
BR (1) BR112020020078A2 (https=)
CA (1) CA3095839A1 (https=)
EA (1) EA202092036A1 (https=)
IL (1) IL277744A (https=)
MX (1) MX2020010618A (https=)
SG (1) SG11202009706VA (https=)
TW (1) TW202010500A (https=)
WO (1) WO2019196803A1 (https=)
ZA (1) ZA202005772B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774813A4 (en) 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
KR20230049580A (ko) * 2020-03-26 2023-04-13 헵테얼즈 테라퓨틱스 리미티드 트리아졸론 화합물
WO2021191376A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
WO2022087146A1 (en) 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
CN113773327B (zh) * 2021-09-13 2022-07-15 八叶草健康产业研究院(厦门)有限公司 一种吡唑并嘧啶并三唑环类化合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110219T2 (de) 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
MXPA04003277A (es) 2001-10-08 2004-07-23 Hoffmann La Roche Amida del acido 8-amino-?1,2,4?triazolo?1,5-a?piridina-6-carboxilico.
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
AU2011306358B2 (en) * 2010-09-24 2014-08-14 Impetis Biosciences Ltd. Fused tricyclic compounds as adenosine receptor antagonist
WO2012135084A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
WO2017136375A1 (en) 2016-02-05 2017-08-10 Concert Pharmaceuticals, Inc. Deuterated tozadenant
EP3774813A4 (en) 2018-04-08 2021-11-17 BeiGene, Ltd. PYRAZOLOTRIAZOLOPYRIMIDE DERIVATIVES AS A2A RECEPTOR ANTAGONIST
CN110742893B (zh) 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法

Also Published As

Publication number Publication date
SG11202009706VA (en) 2020-10-29
TW202010500A (zh) 2020-03-16
MX2020010618A (es) 2020-11-12
KR20200140849A (ko) 2020-12-16
US20210198267A1 (en) 2021-07-01
AU2019251148A1 (en) 2020-10-22
EP3774813A1 (en) 2021-02-17
US11472811B2 (en) 2022-10-18
CN112313234A (zh) 2021-02-02
WO2019196803A1 (en) 2019-10-17
BR112020020078A2 (pt) 2021-01-05
JP2021520392A (ja) 2021-08-19
CA3095839A1 (en) 2019-10-17
ZA202005772B (en) 2022-01-26
EP3774813A4 (en) 2021-11-17
CN112313234B (zh) 2022-04-29
IL277744A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
EA202092036A1 (ru) Производные пиразолотриазолопиримидина в качестве антагониста рецептора a2a
CY1124669T1 (el) ΑΝΤΙ-ΟΙΣΤΡΟΓΟΝΙΚΑ ΦΑΡΜΑΚΑ ΤΕΤΡΑΫΔΡΟ-1Η-ΠΥΡΙΔΟ[3,4-b]INΔOΛIOY
TR201903322T4 (tr) Kinaz inhibisyonu için heteroaril bileşikleri.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX2019013954A (es) Inhibidores covalentes de kras.
CY1125784T1 (el) Υποκατεστημενες δικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις της prmt5
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
MX2021000310A (es) Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de las enfermedades que dependen de la familia de dedo de zinc ikaros (ikzf2).
EA201991693A1 (ru) Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
EA202193015A1 (ru) Ингибиторы cdk
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
MX393879B (es) Métodos de preparación de niraparib.
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
EA201790164A1 (ru) Комбинированная терапия рака
MX2024015576A (es) Tratamiento para migra?as
MX2021007247A (es) Derivados de rapamicina.
CY1112366T1 (el) Ενωσεις βενζιμιδαζολης- καρβοξαμιδης ως αγωνιστες του 5-ητ4 υποδοχεα
EA201692300A1 (ru) Производные карбоксамида
EA202090385A1 (ru) Новые промежуточные соединения, используемые для синтеза производных аминопиримидина, способ их получения и способ получения производных аминопиримидина с их использованием
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
EA201891342A1 (ru) Изоиндольные соединения
EA202190153A1 (ru) Составы ингибитора axl/mer